Follow-up schedule for initial recurrent hepatocellular carcinoma after ablation based on risk classification

por Sun, Xuqi, Li, Lingling, Lyu, Ning, Mu, Luwen, Lai, Jinfa, Zhao, Ming
Publicado 2020

Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients?

por Sun, Xuqi, Hu, Dandan, Zhang, Yaojun, Lyu, Ning, Xu, Li, Chen, Qifeng, Lai, Jinfa, Chen, Minshan, Zhao, Ming
Publicado 2020

Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy

por Liu, Shousheng, Lai, Jinfa, Lyu, Ning, Xie, Qiankun, Cao, Huijiao, Chen, Dabiao, He, Meng, Zhang, Bei, Zhao, Ming
Publicado 2021

Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study

por Lyu, Ning, Kong, Yanan, Li, Xiaoxian, Mu, Luwen, Deng, Haijing, Chen, Huiming, He, Meng, Lai, Jinfa, Li, Jibin, Tang, Hailin, Lin, Youen, Zhao, Ming
Publicado 2020

Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma

por Deng, Haijing, Kan, Anna, Lyu, Ning, He, Meng, Huang, Xin, Qiao, Shuang, Li, Shaolong, Lu, Wenhua, Xie, Qiankun, Chen, Huiming, Lai, Jinfa, Chen, Qifeng, Jiang, Xiongying, Liu, Shousheng, Zhang, Zhenfeng, Zhao, Ming
Publicado 2021